Suppression of Transforming Growth Factor-β₁ Gene Expression by Danggui Buxue Tang, a Traditional Chinese Herbal Preparation, in Retarding the Progress of Renal Damage in Streptozotocin-induced Diabetic Rats

Abstract

Danggui buxue tang (DBT), a preparation containing Angelica sinensis (danggui) and Astragalus membranaceus (huangqi) at a ratio of 1 : 5, is used widely in China for stimulating red blood cell production and enhancing cardiovascular function. The present study was undertaken to characterize the effects of this preparation on diabetic nephropathy using streptozotocin-diabetic rats as a model. Streptozotocin-dependent alterations in renal weight/body weight ratio, urinary albumin and β₂-microglobulin concentrations, urinary albumin excretion rate, and creatinine clearance were ameliorated after eight weeks of treatment with either DBT or the angiotensin-converting enzyme inhibitor, benazepril. DBT, but not benazepril, partially attenuated the increases in blood glucose, triglycerides and cholesterol in STZ-diabetic rats. Additionally, the increased expression of transforming growth factor-β₁ mRNA in the renal cortex due to streptozotocin-induced diabetes was modestly attenuated by these treatments. However, eight weeks of treatment with DBT failed to modify the concentration of angiotensin II in plasma or kidney, indicating that the ability of the preparation to retard the progression of kidney disease was not attributable to inhibition of the renin-angiotensin system. We propose that DBT alleviates renal alterations in diabetes and slows the progression of diabetic nephropathy by suppressing transforming growth factor-β₁ mRNA expression. The preparation may therefore be useful as an adjuvant therapy for controlling diabetes and its complications.

Key words

Angelica sinensis - angiotensin II - astragalus membranaceus - benazepril - danggui buxue tang - nephropathy - type 1 diabetes

References

• 1 Ning L, Chen C X, Jin R M, Wu Y P, Zhang H G, Sun C L, Song C Q, Hu Z B. Effect of components of dang-gui-bu-xue decoction on hematopenia.  Zhongguo Zhong Yao Za Zhi. 2002;  27 50-53
• 2 Song Z H, Ji Z N, Lo C K, Dong T T, Zhao K J, Li O T, Haines C J, Kung S D, Tsim K W. Chemical and biological assessment of a traditional chinese herbal decoction prepared from Radix Astragali and Radix Angelicae Sinensis: orthogonal array design to optimize the extraction of chemical constituents.  Planta Med. 2004;  70 1222-1227
• 3 Hsieh C C, Lin W C, Lee M R, Hsu S L, Liu H S, Kao S T, Hsieh M T. Dang-Gui-Bu-Xai-Tang modulated the immunity of tumor bearing mice.  Immunopharmacol Immunotoxicol. 2003;  25 259-271
• 4 Huntley A L, Ernst E. A systematic review of herbal medicinal products for the treatment of menopausal symptoms.  Menopause. 2003;  10 465-476
• 5 Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G, Cavallo P erin . Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study.  Diabetes Care. 2003;  26 2150-2155
• 6 Makino H, Nakamura Y, Wada J. Remission and regression of diabetic nephropathy.  Hypertens Res. 2003;  26 515-519
• 7 Cai Q, Li X, Wang H. Astragali and Angelica protect the kidney against ischemia and reperfusion injury and accelerate recovery.  Chin Med J (Engl). 2001;  114 119-123
• 8 Zhang S L, To C, Chen X, Filep J G, Tang S S, Ingelfinger J R, Chan J S. Essential role(s) of the intrarenal renin-angiotensin system in transforming growth factor-beta1 gene expression and induction of hypertrophy of rat kidney proximal tubular cells in high glucose.  J Am Soc Nephrol. 2002;  13 302-312
• 9 Locatelli F, Canaud B, Eckardt K U, Stenvinkel P, Wanner C, Zoccali C. The importance of diabetic nephropathy in current nephrological practice.  Nephrol Dial Transpl. 2003;  18 1716-1725
• 10 Dominguez J H, Tang N, Xu W, Evan A P, Siakotos A N, Agarwal R, Walsh J, Deeg M, Pratt J H, March K L, Monnier V M, Weiss M F, Baynes J W, Peterson R. Studies of renal injury III: lipid-induced nephropathy in type II diabetes.  Kidney Int. 2000;  57 92-104
• 11 Dahlquist G, Stattin E L, Rudberg S. Urinary albumin excretion rate and glomerular filtration rate in the prediction of diabetic nephropathy; a long-term follow-up study of childhood onset type-1 diabetic patients.  Nephrol Dial Transplant. 2001;  16 1382-1386
• 12 Peng A, Gu Y, Lin S Y. Herbal treatment for renal diseases.  Ann Acad Med Singapore. 2005;  34 44-51
• 13 Schrijvers B F, DeVriese A S, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines.  Endocr Rev. 2004;  25 971-1010
• 14 Schnaper H W, Hayashida T, Hubchak S C, Poncelet A C. TGF-beta signal transduction and mesangial cell fibrogenesis.  Am J Physiol Renal Physiol. 2003;  284 243-252
• 15 Miyazono K. TGF-beta signaling by Smad proteins.  Cytokine Growth Factor Rev. 2000;  11 15-22
• 16 Cruzado J M, Lloberas N, Torras J, Riera M, Fillat C, Herrero-Fresneda I, Aran J M, Alperovich G, Vidal A, Grinyo J M. Regression of advanced diabetic nephropathy by hepatocyte growth factor gene therapy in rats.  Diabetes. 2004;  53 1119-1127
• 17 Hong S W, Isono M, Chen S, Iglesias-De La Cruz M C, Han D C, Ziyadeh F N. Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse.  Am J Pathol. 2001;  158 1653-1663
• 18 Ziyadeh F N. Mediators of diabetic renal disease: the case for TGF-Beta as the major mediator.  J Am Soc Nephrol. 2004;  15 S55-S57
• 19 Parving H H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.  New Engl J Med. 2001;  345 870-878
• 20 Huang X R, Chen W Y, Truong L D. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease.  J Am Soc Nephrol. 2003;  14 1738-1747
• 21 Li J H, Huang X R, Zhu H J, Johnson R, Lan H Y. Role of TGF-beta signaling in extracellular matrix production under high glucose conditions.  Kidney Int. 2003;  63 2010-2019
• 22 Tian Y C, Fraser D, Attisano L, Phillips A O. TGF-beta1-mediated alterations of renal proximal tubular epithelial cell phenotype.  Am J Physiol Renal Physiol. 2003;  285 130-142
• 23 Monkawa T, Hiromura K, Wolf G, Shankland S J. The hypertrophic effect of transforming growth factor-beta is reduced in the absence of cyclin-dependent kinase-inhibitors p21 and p27.  J Am Soc Nephrol. 2002;  13 1172-1178
• 24 Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, Gagliardini E, Rottoli D, Zanchi C, Abbate M, Ledbetter S, Remuzzi G. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat.  J Am Soc Nephrol. 2003;  14 1816-1824
• 25 Ma J, Peng A, Lin S. Mechanisms of the therapeutic effect of astragalus membranaceus on sodium and water retention in experimental heart failure.  Chin Med J. 1998;  111 17-23
• 26 Yu L, Li J Z, Wang H Y. Research on the application of astragali and angelica in treating renal disease and its mechanisms.  Zhongguo Zhong Xi Yi Jie He Za Zhi. 2001;  21 396-399
• 27 Cheng J T. Review: drug therapy in Chinese traditional medicine.  J Clin Pharmacol. 2000;  40 445-450
• 28 Huang W H, Song C Q. Research progresses in the chemistry and pharmacology of Angelica sinensis (Oliv.) Diel.  Zhongguo Zhong Yao Za Zhi. 2001;  26 47-151